Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

Advances in Urology

Volumn 2018, Issue , 2018, Pages

  Fung, Chunkit ^a   Dinh, Paul ^b   Ardeshir Rouhani Fard, Shirin ^b   Schaffer, Kerry ^a   Fossa, Sophie D ^c   Travis, Lois B ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85043518503     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2018/8671832     Document Type: Review

References (169)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer Statistics, 2017," CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7-30, 2017.
2. L. H. Einhorn and J. Donohue, "Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer," Annals of Internal Medicine, vol. 87, no. 3, pp. 293-298, 1977.
3. N. Hanna and L. H. Einhorn, "Testicular cancer: a reGection on 50 years of discovery," Journal of Clinical Oncology, vol. 32, no. 28, pp. 3085-3092, 2014.
4. A. Verdecchia, S. Francisci, H. Brenner et al., "Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data," Lancet Oncology, vol. 8, no. 9, pp. 784-796, 2007.
5. L. H. Einhorn, "Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture," Cancer Research, vol. 41, no. 1, pp. 3275-3280, 1981.
6. L. B. Travis, A. K. Ng, J. M. Allan et al., "Second malignant neoplasms and cardiovascular disease following radiotherapy," Journal of the National Cancer Institute, vol. 104, no. 5, pp. 357-370, 2012.
7. H. S. Haugnes, G. J. Bosl, H. Boer et al., "Long-term and late e6ects of germ cell testicular cancer treatment and implications for follow-up," Journal of Clinical Oncology, vol. 30, no. 30, pp. 3752-3763, 2012.
8. N. M. Aziz, "Cancer survivorship research: state of knowledge, challenges and opportunities," Acta Oncologica, vol. 46, no. 4, pp. 417-432, 2007.
9. D. R. Feldman, W. L. Scha6er, and R. M. Steingart, "Late cardiovascular toxicity following chemotherapy for germ cell tumors," Journal of the National Comprehensive Cancer Network, vol. 10, no. 4, pp. 537-544, 2012.
10. J. F. Christensen, M. Bandak, A. Campbell, L. W. Jones, and P. Højman, "Treatment-related cardiovascular late e6ects and exercise training countermeasures in testicular germ cell cancer survivorship," Acta Oncologica, vol. 54, no. 5, pp. 592-599, 2015.
11. L. Y. Dirix, M. Libura, J. Libura, P. B. Vermeulen, E. A De Bruijn, and A. T. Van Oosterom, "In vitro toxicity studies with mitomycins and bleomycin on endothelial cells," Anticancer Drugs, vol. 8, no. 9, pp. 859-868, 1997.
12. Y. Shi, S. Inoue, R. Shinozaki, K. Fukue, and T. Kougo, "Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro," Japanese Journal of Cancer Research, vol. 89, no. 7, pp. 757-767, 1998.
13. K. P. Dieckmann, W. J. Struss, and U. Budde, "Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour," Anticancer Research, vol. 31, no. 12, pp. 4501-4505, 2011.
14. J. Nuver, A. J. Smit, D. T. Sleijfer et al., "Microalbuminuria, decreased Dbrinolysis, and inGammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer," European Journal of Cancer, vol. 40, no. 5, pp. 701-706, 2004.
15. J. Nuver, A. J. Smit, J. van der Meer et al., "Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer," Journal of Clinical Oncology, vol. 23, no. 36, pp. 9130-9137, 2005.
16. M. T. Meinardi, J. A. Gietema, W. T. van der Graaf et al., "Cardiovascular morbidity in long-term survivors of metastatic testicular cancer," Journal of Clinical Oncology, vol. 18, no. 8, pp. 1725-1732, 2000.
17. H. C. Gerstein, J. F. Mann, Q. Yi et al., "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals," Journal of the American Medical Association, vol. 286, no. 4, pp. 421-426, 2001.
18. D. H. O'Leary, J. F. Polak, R. A. Kronmal et al., "Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group," New England Journal of Medicine, vol. 340, no. 1, pp. 14-22, 1999.
19. L. D. van Schinkel, P. M. Willemse, R. W. van der Meer et al., "Chemotherapy for testicular cancer induces acute alterations in diastolic heart function," British Journal of Cancer, vol. 109, no. 4, pp. 891-896, 2013.
20. D. J. Brenner and E. J. Hall, "Computed tomography-an increasing source of radiation exposure," New England Journal of Medicine, vol. 357, no. 22, pp. 2277-2284, 2007.
21. R. L. Schilsky and T. Anderson, "Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin," Annals of Internal Medicine, vol. 90, no. 6, pp. 929-931, 1979.
22. P. D. Turlapaty and B. M. Altura, "Magnesium deDciency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease," Science, vol. 208, no. 4440, pp. 198-200, 1980.
23. N. J. Vogelzang, J. L. Torkelson, and B. J. Kennedy, "Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin," Cancer, vol. 56, no. 12, pp. 2765-2770, 1985.
24. G. I. Togna, A. R. Togna, M. Franconi, and L. Caprino, "Cisplatin triggers platelet activation," rombosis Research, vol. 99, no. 5, pp. 503-509, 2000.
25. D. Lechner, M. Kollars, A. Gleiss, P. A. Kyrle, and A. Weltermann, "Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity," Journal of rombosis and Haemostasis, vol. 5, no. 12, pp. 2445-2452, 2007.
26. D. Bissett, L. Kunkeler, L. Zwanenburg et al., "Long-term sequelae of treatment for testicular germ cell tumours," British Journal of Cancer, vol. 62, no. 4, pp. 655-659, 1990.
27. C. Bokemeyer and H. J. Schmoll, "Secondary neoplasms following treatment of malignant germ cell tumors," Journal of Clinical Oncology, vol. 11, no. 9, pp. 1703-1709, 1993.
28. M. Brydoy, J. Oldenburg, O. Klepp et al., "Observational study of prevalence of long-term Raynaud-like phenomena and neurological side e6ects in testicular cancer survivors," Journal of the National Cancer Institute, vol. 101, no. 24, pp. 1682-1695, 2009.
29. J. L. Glendenning, Y. Barbachano, A. R. Norman et al., "Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer," Cancer, vol. 116, no. 10, pp. 2322-2331, 2010.
30. D. Strumberg, S. Brugge, M. W. Korn et al., "Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer," Annals of Oncology, vol. 13, no. 2, pp. 229-236, 2002.
31. R. de Wit, G. Stoter, S. B. Kaye et al., "Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group," Journal of Clinical Oncology, vol. 15, no. 5, pp. 1837-1843, 1997.
32. C. Bokemeyer, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll, "Evaluation of long-term toxicity after chemotherapy for testicular cancer," Journal of Clinical Oncology, vol. 14, no. 11, pp. 2923-2932, 1996.
33. H. S. Haugnes, N. Aass, S. D. Fossa et al., "Components of the metabolic syndrome in long-term survivors of testicular cancer," Annals of Oncology, vol. 18, no. 2, pp. 241-248, 2007.
34. H. S. Haugnes, T. Wethal, N. Aass et al., "Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study," Journal of Clinical Oncology, vol. 28, no. 30, pp. 4649-4657, 2010.
35. R. A. Huddart, A. Norman, M. Shahidi et al., "Cardiovascular disease as a long-term complication of treatment for testicular cancer," Journal of Clinical Oncology, vol. 21, no. 8, pp. 1513-1523, 2003.
36. J. Nuver, A. J. Smit, B. H. Wol6enbuttel et al., "E metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer," Journal of Clinical Oncology, vol. 23, no. 16, pp. 3718-3725, 2005.
37. H. Sagstuen, N. Aass, S. D. Fossa et al., "Blood pressure and body mass index in long-term survivors of testicular cancer," Journal of Clinical Oncology, vol. 23, no. 22, pp. 4980-4990, 2005.
38. P. M. Willemse, J. Burggraaf, N. A. Hamdy et al., "Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors," British Journal of Cancer, vol. 109, no. 1, pp. 60-67, 2013.
39. E. C. de Haas, R. Altena, H. M. Boezen et al., "Early development of the metabolic syndrome after chemotherapy for testicular cancer," Annals of Oncology, vol. 24, no. 3, pp. 749-755, 2013.
40. C. Fung, H. D. Sesso, A. M. Williams et al., "Multiinstitutional assessment of adverse health outcomes among north American testicular cancer survivors after modern cisplatin-based chemotherapy," Journal of Clinical Oncology, vol. 35, no. 11, pp. 1211-1222, 2017.
41. C. Bogefors, S. Isaksson, J. Bobjer et al., "Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome," Andrology, vol. 5, no. 4, pp. 711-717, 2017.
42. A. M. Traish, F. Saad, R. J. Feeley, and A. Guay, "E dark side of testosterone deDciency: III. Cardiovascular disease," Journal of Andrology, vol. 30, no. 5, pp. 477-494, 2009.
43. A. M. Traish, F. Saad, and A. Guay, "E dark side of testosterone deDciency: II. Type 2 diabetes and insulin resistance," Journal of Andrology, vol. 30, no. 5, pp. 23-32, 2009.
44. A. M. Traish, A. Guay, R. Feeley, and F. Saad, "E dark side of testosterone deDciency: I. Metabolic syndrome and erectile dysfunction," Journal of Andrology, vol. 30, no. 5, pp. 10-22, 2009.
45. L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey, "Early breast cancer therapy and cardiovascular injury," Journal of the American College of Cardiology, vol. 50, no. 15, pp. 1435-1441, 2007.
46. A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema et al., "Treatment-speciDc risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer," Journal of Clinical Oncology, vol. 25, no. 28, pp. 4370-4378, 2007.
47. A. W. van den Belt-Dusebout, J. Nuver, R. de Wit et al., "Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer," Journal of Clinical Oncology, vol. 24, no. 3, pp. 467-475, 2006.
48. S. D. Fossa, E. Gilbert, G. M. Dores et al., "Noncancer causes of death in survivors of testicular cancer," Journal of the National Cancer Institute, vol. 99, no. 7, pp. 533-544, 2007.
49. S. R. Alanee, D. R. Feldman, P. Russo et al., "Long-term mortality in patients with germ cell tumors: e6ect of primary cancer site on cause of death," Urologic Oncology, vol. 32, no. 1, pp. 26.e9-26.e15, 2014.
50. C. Fung, S. D. Fossa, M. T. Milano et al., "Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study," Journal of Clinical Oncology, vol. 33, no. 28, pp. 3105-3115, 2015.
51. A. S. Go, D. Moza6arian, V. L. Roger et al., "Heart disease and stroke statistics-2014 update: a report from the American Heart Association," Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
52. D. C. Go6 Jr., D. M. Lloyd-Jones, G. Bennett et al., "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines," Circulation, vol. 129, no. 2, pp. S49-S73, 2013.
53. M. E. Wood, V. Vogel, A. Ng, L. Foxhall, P. Goodwin, and L. B. Travis, "Second malignant neoplasms: assessment and strategies for risk reduction," Journal of Clinical Oncology, vol. 30, no. 30, pp. 3734-3745, 2012.
54. L. B. Travis, C. S. Rabkin, L. M. Brown et al., "Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations," Journal of the National Cancer Institute, vol. 98, no. 1, pp. 15-25, 2006.
55. L. B. Travis, S. D. Fossa, S. J. Schonfeld et al., "Second cancers among 40,576 testicular cancer patients: focus on long-term survivors," Journal of the National Cancer Institute, vol. 97, no. 18, pp. 1354-1365, 2005.
56. L. B. Travis, M. Andersson, M. Gospodarowicz et al., "Treatment-associated leukemia following testicular cancer," Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1165-1171, 2000.
57. L. B. Travis, R. E. Curtis, H. Storm et al., "Risk of second malignant neoplasms among long-term survivors of testicular cancer," Journal of the National Cancer Institute, vol. 89, no. 19, pp. 1429-1439, 1997.
58. M. Hauptmann, S. D. Fossa, M. Stovall et al., "Increased stomach cancer risk following radiotherapy for testicular cancer," British Journal of Cancer, vol. 112, no. 1, pp. 44-51, 2015.
59. M. Hauptmann, T. Borge Johannesen, E. S. Gilbert et al., "Increased pancreatic cancer risk following radiotherapy for testicular cancer," British Journal of Cancer, vol. 115, no. 7, pp. 901-908, 2016.
60. A. W. van den Belt-Dusebout, B. M. Aleman, G. Besseling et al., "Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy," International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 5, pp. 1420-1429, 2009.
61. J. M. Bachaud, F. Berthier, M. Soulie et al., "Second nongerm cell malignancies in patients treated for stage I-II testicular seminoma," Radiotherapy and Oncology, vol. 50, no. 2, pp. 191-197, 1999.
62. N. H. Hanna and L. H. Einhorn, "Testicular cancer-discoveries and updates," New England Journal of Medicine, vol. 371, no. 21, pp. 2005-2016, 2014.
63. D. F. Bajorin, M. F. Sarosdy, D. G. PDster et al., "Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study," Journal of Clinical Oncology, vol. 11, no. 4, pp. 598-606, 1993.
64. C. Kollmannsberger, J. Beyer, J. P. Droz et al., "Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors," Journal of Clinical Oncology, vol. 16, no. 10, pp. 3386-3391, 1998.
65. C. Kollmannsberger, J. T. Hartmann, L. Kanz et al., "Erapy-related malignancies following treatment of germ cell cancer," International Journal of Cancer, vol. 83, no. 6, pp. 860-863, 1999.
66. E. H. Wanderas, S. D. Fossa, and S. Tretli, "Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients," European Journal of Cancer, vol. 33, no. 2, pp. 253-262, 1997.
67. C. Fung, S. D. Fossa, M. T. Milano, J. Oldenburg, and L. B. Travis, "Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study," Journal of Clinical Oncology, vol. 31, no. 30, pp. 3807-3814, 2013.
68. S. D. Fossa, J. Chen, S. J. Schonfeld et al., "Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men," Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1056-1066, 2005.
69. P. B. Rossen, A. F. Pedersen, R. Zachariae, and H. von der Maase, "Health-related quality of life in long-term survivors of testicular cancer," Journal of Clinical Oncology, vol. 27, no. 35, pp. 5993-5999, 2009.
70. S. D. Williams, R. Birch, L. H. Einhorn, L. Irwin, F. A. Greco, and P. J. Loehrer, "Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide," New England Journal of Medicine, vol. 316, no. 23, pp. 1435-1440, 1987.
71. M. Sprauten, T. H. Darrah, D. R. Peterson et al., "Impact of long-term serum platinum concentrations on neuro-and ototoxicity in Cisplatin-treated survivors of testicular cancer," Journal of Clinical Oncology, vol. 30, no. 3, pp. 300-307, 2012.
72. J. Oldenburg, S. M. Kraggerud, M. Brydoy, M. Cvancarova, R. A. Lothe, and S. D. Fossa, "Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross sectional study," Journal of Translational Medicine, vol. 5, no. 1, p. 70, 2007.
73. M. E. Dolan, O. El Charif, H. E. Wheeler et al., "Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer," Clinical Cancer Research, vol. 23, no. 19, pp. 5757-5768, 2017.
74. A. Sawant, A. Kothandapani, A. Zhitkovich, R. W. Sobol, and S. M. Patrick, "Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links," DNA Repair, vol. 35, pp. 126-136, 2015.
75. J. C. Morales, P. Richard, A. Rommel et al., "Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair," Nucleic Acids Research, vol. 42, no. 8, pp. 4996-5006, 2014.
76. D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline," Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941-1967, 2014.
77. C. A. Bauer and T. J. Brozoski, "Cochlear structure and function after round window application of ototoxins," Hearing Research, vol. 201, no. 1-2, pp. 121-131, 2005.
78. C. Bokemeyer, C. C. Berger, J. T. Hartmann et al., "Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer," British Journal of Cancer, vol. 77, no. 8, pp. 1355-1362, 1998.
79. R. D. Frisina, H. E. Wheeler, S. D. Fossa et al., "Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer," Journal of Clinical Oncology, vol. 34, no. 23, pp. 2712-2720, 2016.
80. L. P. Rybak, "Mechanisms of cisplatin ototoxicity and progress in otoprotection," Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 15, no. 5, pp. 364-369, 2007.
81. L. Riedemann, C. Lanvers, D. Deuster et al., "Megalin genetic polymorphisms and individual sensitivity to the ototoxic e6ect of cisplatin," Pharmacogenomics Journal, vol. 8, no. 1, pp. 23-28, 2008.
82. J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa, "Cisplatin-induced long-term hearing impairment is associated with speciDc glutathione s-transferase genotypes in testicular cancer survivors," Journal of Clinical Oncology, vol. 25, no. 6, pp. 708-714, 2007.
83. C. J. Ross, H. Katzov-Eckert, M. P. Dube et al., "Genetic variants in TPMTand COMTare associated with hearing loss in children receiving cisplatin chemotherapy," Nature Genetics, vol. 41, no. 12, pp. 1345-1349, 2009.
84. H. E. Wheeler, E. R. Gamazon, R. D. Frisina et al., "Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity," Clinical Cancer Research, vol. 23, no. 13, pp. 3325-3333, 2016.
85. H. E. Wheeler, R. D. Frisina, E. R. Gamazon et al., "Genomewide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in wolfram syndrome 1 (WFS1) gene," Journal of Clinical Oncology, vol. 34, no. 15, p. 10015, 2016.
86. K. Cryns, T. A. Sivakumaran, J. M. Van den Ouweland et al., "Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease," Human Mutation, vol. 22, no. 4, pp. 275-287, 2003.
87. H. Inoue, Y. Tanizawa, J. Wasson et al., "A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (wolfram syndrome)," Nature Genetics, vol. 20, no. 2, pp. 143-148, 1998.
88. S. D. Fossa, R. de Wit, J. T. Roberts et al., "Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/ Medical Research Council Testicular Cancer Study Group (30941/TE20)," Journal of Clinical Oncology, vol. 21, no. 6, pp. 1107-1118, 2003.
89. J. M. O'Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich, "Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours," Annals of Oncology, vol. 14, no. 1, pp. 91-96, 2003.
90. A. B. Simpson, J. Paul, J. Graham, and S. B. Kaye, "Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours," British Journal of Cancer, vol. 78, no. 8, pp. 1061-1066, 1998.
91. S. Sleijfer, "Bleomycin-induced pneumonitis," Chest, vol. 120, no. 2, pp. 617-624, 2001.
92. H. S. Haugnes, N. Aass, S. D. Fossa et al., "Pulmonary function in long-term survivors of testicular cancer," Journal of Clinical Oncology, vol. 27, no. 17, pp. 2779-2786, 2009.
93. H. S. Haugnes, J. Oldenburg, and R. M. Bremnes, "Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors," Urologic Oncology, vol. 33, no. 9, pp. 399-406, 2015.
94. S. M. Donat and D. A. Levy, "Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?," Journal of Urology, vol. 160, no. 4, pp. 1347-1352, 1998.
95. R. de Wit, S. Sleijfer, S. B. Kaye et al., "Bleomycin and scuba diving: where is the harm?," Lancet Oncology, vol. 8, no. 11, pp. 954-955, 2007.
96. A. A. Ferrando, A. M. Pendas, E. Llano, G. Velasco, R. Lidereau, and C. López-Otn, "Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase," Journal of Biological Chemistry, vol. 272, no. 52, pp. 33298-33304, 1997.
97. J. Nuver, M. F. Lutke Holzik, M. van Zweeden et al., "Genetic variation in the bleomycin hydrolase gene and bleomycininduced pulmonary toxicity in germ cell cancer patients," Pharmacogenetics and Genomics, vol. 15, no. 6, pp. 399-405, 2005.
98. A. E. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley, "Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology," Toxicologic Pathology, vol. 32, no. 5, pp. 577-590, 2004.
99. H. Tanaka, E. Ishikawa, S. Teshima, and E. Shimizu, "Histopathological study of human cisplatin nephropathy," Toxicologic Pathology, vol. 14, no. 2, pp. 247-257, 1986.
100. S. D. Fossa, N. Aass, M. Winderen, O. P. Börmer, and D. R. Olsen, "Long-term renal function after treatment for malignant germ-cell tumours," Annals of Oncology, vol. 13, no. 2, pp. 222-228, 2002.
101. S. W. Hansen, S. Groth, G. Daugaard, N. Rossing, and M. Rørth, "Long-term e6ects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer," Journal of Clinical Oncology, vol. 6, no. 11, pp. 1728-1731, 1988.
102. J. M. Peacock, T. Ohira, W. Post, N. Sotoodehnia, W. Rosamond, and A. R. Folsom, "Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study," American Heart Journal, vol. 160, no. 3, pp. 464-470, 2010.
103. B. C. Astor, S. I. Hallan, E. R. Miller III, E. Yeung, and J. Coresh, "Glomerular Dltration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population," American Journal of Epidemiology, vol. 167, no. 10, pp. 1226-1234, 2008.
104. J. T. Hartmann, C. Kollmannsberger, L. Kanz, and C. Bokemeyer, "Platinum organ toxicity and possible prevention in patients with testicular cancer," International Journal of Cancer, vol. 83, no. 6, pp. 866-869, 1999.
105. M. Sprauten, M. Brydoy, H. S. Haugnes et al., "Longitudinal serum testosterone, luteinizing hormone, and folliclestimulating hormone levels in a population-based sample of long-term testicular cancer survivors," Journal of Clinical Oncology, vol. 32, no. 6, pp. 571-578, 2014.
106. J. Eberhard, O. Stahl, M. Cwikiel et al., "Risk factors for post-treatment hypogonadism in testicular cancer patients," European Journal of Endocrinology, vol. 158, no. 4, pp. 561-570, 2008.
107. C. Nord, T. Bjoro, D. Ellingsen et al., "Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer," European Urology, vol. 44, no. 3, pp. 322-328, 2003.
108. M. Brydoy, S. D. Fossa, O. Dahl, and T. Bjøro, "Gonadal dysfunction and fertility problems in cancer survivors," Acta Oncologica, vol. 46, no. 4, pp. 480-489, 2007.
109. R. A. Huddart, A. Norman, C. Moynihan et al., "Fertility, gonadal and sexual function in survivors of testicular cancer," British Journal of Cancer, vol. 93, no. 2, pp. 200-207, 2005.
110. M. Bandak, N. Jorgensen, A. Juul et al., "Testosterone de-Dciency in testicular cancer survivors-a systematic review and meta-analysis," Andrology, vol. 4, no. 3, pp. 382-388, 2016.
111. J. Eberhard, O. Stahl, G. Cohn-Cedermark et al., "Sexual function in men treated for testicular cancer," Journal of Sexual Medicine, vol. 6, no. 7, pp. 1979-1989, 2009.
112. M. Brydoy, S. D. Fossa, O. Klepp et al., "Paternity following treatment for testicular cancer," Journal of the National Cancer Institute, vol. 97, no. 21, pp. 1580-1588, 2005.
113. A. A. Dahl, R. Bremnes, O. Dahl, O. Klepp, E. Wist, and S. D. Foss?a, "Is the sexual function compromised in longterm testicular cancer survivors?," European Urology, vol. 52, no. 5, pp. 1438-1447, 2007.
114. J. Hintikka, L. Niskanen, H. Koivumaa-Honkanen et al., "Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men," Journal of Sexual Medicine, vol. 6, no. 7, pp. 2049-2057, 2009.
115. S. Bhasin, G. R. Cunningham, F. J. Hayes et al., "Testosterone therapy in men with androgen deDciency syndromes: an Endocrine Society clinical practice guideline," Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 6, pp. 2536-2559, 2010.
116. M. Ondrusova, D. Ondrus, L. Dusek, and B. Spanikova, "Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer," Neoplasma, vol. 56, no. 6, pp. 473-479, 2009.
117. V. Rochira, A. Balestrieri, B. Madeo, L. Zirilli, A. R. Granata, and C. Carani, "Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology," European Journal of Endocrinology, vol. 154, no. 2, pp. 175-185, 2006.
118. M. Abu Zaid, A. G. Menendez, O. E. Charif et al., "Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: a multicenter study of North American testicular cancer survivors (TCS)," Journal of Clinical Oncology, vol. 35, no. 18, 2017.
119. S. D. Fossa, T. Abyholm, and A. Aakvaag, "Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment," European Urology, vol. 10, no. 3, pp. 173-177, 1984.
120. K. P. Dieckmann, J. Linke, U. Pichlmeier, M. Kulejewski, and V. Loy, "Spermatogenesis in the contralateral testis of patients with testicular germ cell cancer: histological evaluation of testicular biopsies and a comparison with healthy males," BJU International, vol. 99, no. 5, pp. 1079-1085, 2007.
121. E. Huyghe, T. Matsuda, M. Daudin et al., "Fertility after testicular cancer treatments: results of a large multicenter study," Cancer, vol. 100, no. 4, pp. 732-737, 2004.
122. J. R. Spermon, L. A. Kiemeney, E. J. Meuleman, L. Ramos, A. M. M. Wetzels, and J. A. Witjes, "Fertility in men with testicular germ cell tumors," Fertility and Sterility, vol. 79, pp. 1543-1549, 2003.
123. M. Brydoy, S. D. Fossa, O. Klepp et al., "Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy," European Urology, vol. 58, no. 1, pp. 134-140, 2010.
124. W. Gordon Jr., K. Siegmund, T. H. Stanisic et al., "A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group," International Journal of Radiation Oncology Biology Physics, vol. 38, no. 1, pp. 83-94, 1997.
125. M. Brydoy, S. D. Fossa, O. Klepp et al., "Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer," British Journal of Cancer, vol. 107, no. 11, pp. 1833-1839, 2012.
126. K. A. Ostrowski and T. J. Walsh, "Infertility with testicular cancer," Urologic Clinics of North America, vol. 42, no. 3, pp. 409-420, 2015.
127. L. Gandini, P. Sgro, F. Lombardo et al., "E6ect of chemo-or radiotherapy on sperm parameters of testicular cancer patients," Human Reproduction, vol. 21, no. 11, pp. 2882-2889, 2006.
128. H. Lampe, A. Horwich, A. Norman et al., "Fertility after chemotherapy for testicular germ cell cancers," Journal of Clinical Oncology, vol. 15, no. 1, pp. 239-245, 1997.
129. S. D. Beck, A. L. Bey, R. Bihrle et al., "Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection," Journal of Urology, vol. 184, no. 5, pp. 2078-2080, 2010.
130. V. S. Subramanian, C. T. Nguyen, A. J. Stephenson et al., "Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer," Urologic Oncology, vol. 28, no. 5, pp. 504-509, 2010.
131. A. Heidenreich, P. Albers, M. Hartmann et al., "Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group," Journal of Urology, vol. 169, no. 5, pp. 1710-1714, 2003.
132. K. D. Jacobsen, S. Ous, H. Waehre et al., "Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection," British Journal of Cancer, vol. 80, no. 1-2, pp. 249-255, 1999.
133. J. A. Pettus, B. S. Carver, T. Masterson, J. Stasi, and J. Sheinfeld, "Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer," Urology, vol. 73, no. 2, pp. 328-331, 2009.
134. C. L. Coogan, M. J. Hejase, G. R. Wahle et al., "Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer," Journal of Urology, vol. 156, no. 5, pp. 1656-1658, 1996.
135. A. Heidenreich, D. PDster, R. Witthuhn, D. Uer, and P. Albers, "Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modiDed template resection," European Urology, vol. 55, no. 1, pp. 217-224, 2009.
136. A. W. Loren, P. B. Mangu, L. N. Beck et al., "Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update," Journal of Clinical Oncology, vol. 31, no. 19, pp. 2500-2510, 2013.
137. E. W. Winquist, G. S. Bauman, and J. Balogh, "Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review," American Journal of Clinical Oncology, vol. 24, no. 6, pp. 603-606, 2001.
138. A. M. Cook, A. S. Dzik-Jurasz, A. R. Padhani, A. Norman, and R. A. Huddart, "Eprevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours," British Journal of Cancer, vol. 85, no. 11, pp. 1624-1626, 2001.
139. R. Kaila and R. L. Wolman, "Groin pain in athletes: a consequence of femoral head avascular necrosis after testicular cancer chemotherapy," Clinical Journal of Sport Medicine, vol. 16, no. 2, pp. 175-176, 2006.
140. F. van den Berkmortel, R. de Wit, J. de Rooy, and P. DeMulder, "Osteonecrosis in patients with testicular tumours treated with chemotherapy," Netherlands Journal of Medicine, vol. 62, no. 1, pp. 23-27, 2004.
141. P. G. Harper, C. Trask, and R. L. Souhami, "Avascular necrosis of bone caused by combination chemotherapy without corticosteroids," British Medical Journal, vol. 288, no. 6413, pp. 267-268, 1984.
142. M. B. de Ruiter, L. Reneman, W. Boogerd et al., "Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer," Human Brain Mapping, vol. 32, no. 8, pp. 1206-1219, 2011.
143. S. R. Kesler, F. C. Bennett, M. L. Maha6ey, and D. Spiegel, "Regional brain activation during verbal declarative memory in metastatic breast cancer," Clinical Cancer Research, vol. 15, no. 21, pp. 6665-6673, 2009.
144. D. H. Silverman, C. J. Dy, S. A. Castellon et al., "Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy," Breast Cancer Research and Treatment, vol. 103, no. 3, pp. 303-311, 2007.
145. B. Weiss, "Chemobrain: a translational challenge for neurotoxicology," Neurotoxicology, vol. 29, no. 5, pp. 891-898, 2008.
146. A. Amidi, L. M. Wu, M. Agerbaek et al., "Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients," Psycho-Oncology, vol. 24, no. 9, pp. 1174-1180, 2015.
147. J. S. Wefel, D. J. Vidrine, T. L. Veramonti et al., "Cognitive impairment in men with testicular cancer prior to adjuvant therapy," Cancer, vol. 117, no. 1, pp. 190-196, 2011.
148. S. B. Schagen, W. Boogerd, M. J. Muller et al., "Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer," Acta Oncologica, vol. 47, no. 1, pp. 63-70, 2008.
149. A. D. Pedersen, P. Rossen, M. Y. Mehlsen et al., "Long-term cognitive function following chemotherapy in patients with testicular cancer," Journal of the International Neuropsychological Society, vol. 15, no. 2, pp. 296-301, 2009.
150. T. Skaali, S. D. Fossa, S. Andersson et al., "Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress," Journal of Psychosomatic Research, vol. 70, no. 5, pp. 403-410, 2011.
151. J. Skoogh, G. Steineck, U. Stierner et al., "Testicular-cancer survivors experience compromised language following chemotherapy: Dndings in a Swedish population-based study 3-26 years after treatment," Acta Oncologica, vol. 51, no. 2, pp. 185-197, 2012.
152. J. S. Wefel, D. J. Vidrine, S. K. Marani et al., "A prospective study of cognitive function in men with non-seminomatous germ cell tumors," Psycho-Oncology, vol. 23, no. 6, pp. 626-633, 2014.
153. A. A. Dahl, C. F. Haaland, A. Mykletun et al., "Study of anxiety disorder and depression in long-term survivors of testicular cancer," Journal of Clinical Oncology, vol. 23, no. 10, pp. 2389-2395, 2005.
154. S. Vehling, A. Mehnert, M. Hartmann, C. Oing, C. Bokemeyer, and K. Oechsle, "Anxiety and depression in long-term testicular germ cell tumor survivors," General Hospital Psychiatry, vol. 38, pp. 21-25, 2016.
155. E. H. Shinn, K. Basen-Engquist, B. Ornton, P. E. Spiess, and L. Pisters, "Health behaviors and depressive symptoms in testicular cancer survivors," Urology, vol. 69, no. 4, pp. 748-753, 2007.
156. A. B. Smith, P. Butow, I. Olver et al., "Eprevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study," Journal of Cancer Survivorship, vol. 10, no. 2, pp. 223-233, 2016.
157. J. E. Bower, "Cancer-related fatigue-mechanisms, risk factors, and treatments," Nature Reviews Clinical Oncology, vol. 11, no. 10, pp. 597-609, 2014.
158. I. J. Orre, S. D. Fossa, R. Murison et al., "Chronic cancerrelated fatigue in long-term survivors of testicular cancer," Journal of Psychosomatic Research, vol. 64, no. 4, pp. 363-371, 2008.
159. M. Sprauten, H. S. Haugnes, M. Brydoy et al., "Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors," Annals of Oncology, vol. 26, no. 10, pp. 2133-2140, 2015.
160. K. M. Mustian, C. M. Alfano, C. Heckler et al., "Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis," JAMA Oncology, vol. 3, no. 7, pp. 961-968, 2017.
161. L. B. Travis, C. Beard, J. M. Allan et al., "Testicular cancer survivorship: research strategies and recommendations," Journal of the National Cancer Institute, vol. 102, no. 15, pp. 1114-1130, 2010.
162. K. D. Miller, R. L. Siegel, C. C. Lin et al., "Cancer treatment and survivorship statistics, 2016," CA: A Cancer Journal for Clinicians, vol. 66, no. 4, pp. 271-289, 2016.
163. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)," Journal of the American Medical Association, vol. 285, no. 19, pp. 2486-2497, 2001.
164. L. Richiardi, G. Scelo, P. Bo6etta et al., "Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries," International Journal of Cancer, vol. 120, no. 3, pp. 623-631, 2007.
165. K. Hemminki, H. Liu, and J. Sundquist, "Second cancers after testicular cancer diagnosed after 1980 in Sweden," Annals of Oncology, vol. 21, no. 7, pp. 1546-1551, 2010.
166. I. M. Ventry and B. E. Weinstein, "Ehearing handicap inventory for the elderly: a new tool," Ear and Hearing, vol. 3, no. 3, pp. 128-134, 1982.
167. European Organisation for Research and Treatment of Cancer, First EORTC Cancer Survivorship Summit, Vol. 12, European Journal of Cancer Supplements, Brussels, Belgium, June 2014.
168. J. Oldenburg, S. D. Fossa, and A. A. Dahl, "Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and Dndings in a large sample of testicular cancer survivors," Quality of Life Research, vol. 15, no. 5, pp. 791-800, 2006.
169. L. B. Travis, "Erapy-associated solid tumors," Acta Oncologica, vol. 41, no. 4, pp. 323-333, 2002.